Syndax Pharmaceuticals (SNDX) Misses Q4 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts SNDX Hot Sheet
Join SI Premium – FREE
Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($1.00), $0.03 worse than the analyst estimate of ($0.97).
For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Xometry, Inc. (XMTR) Tops Q3 EPS by 9c ; Offers Guidance
- Syndax Pharmaceuticals (SNDX) PT Lowered to $36 at H.C. Wainwright
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
